The cholinergic deficit coincides with Abeta deposition at the earliest histopathologic stages of Alzheimer disease. (Q53234222)

12 May 2018

title

The cholinergic deficit coincides with Abeta deposition at the earliest histopathologic stages of Alzheimer disease. (English)

1 reference

12 May 2018

author name string

Beach TG

1 reference

12 May 2018

Kuo YM

1 reference

12 May 2018

Spiegel K

1 reference

12 May 2018

Emmerling MR

1 reference

12 May 2018

Sue LI

1 reference

12 May 2018

Kokjohn K

1 reference

12 May 2018

Roher AE

1 reference

12 May 2018

publication date

1 April 2000

1 reference

12 May 2018

Journal of Neuropathology & Experimental Neurology

published in

1 reference

12 May 2018

volume

1 reference

12 May 2018

issue

1 reference

12 May 2018

page(s)

308-313

1 reference

12 May 2018

Mutant genes in familial Alzheimer's disease and transgenic models

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Choline acetyltransferase activity and histopathology of frontal neocortex from biopsies of demented patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Topographical distribution of neurochemical changes in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Cholinergic fibre loss associated with diffuse plaques in the non-demented elderly: the preclinical stage of Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Clinical, pathological, and neurochemical changes in dementia: A subgroup with preserved mental status and numerous neocortical plaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

The Clinical Dementia Rating (CDR): current version and scoring rules

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Abeta1-40 but not Abeta1-42 levels in cortex correlate with apolipoprotein E epsilon4 allele dosage in sporadic Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Apolipoprotein E, Dementia, and Cortical Deposition of β-Amyloid Protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Neuropathological stageing of Alzheimer-related changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Demonstration of Amyloid Deposits and Neurofibrillary Changes in Whole Brain Sections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Radiochemical micro assays for the determination of choline acetyltransferase and acetylcholinesterase activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Elevated low-density lipoprotein in Alzheimer's disease correlates with brain abeta 1-42 levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Selective loss of central cholinergic neurons in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Necropsy evidence of central cholinergic deficits in senile dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Carboxy terminal of beta-amyloid deposits in aged human, canine, and polar bear brains

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Cholinergic markers in elderly patients with early signs of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Effects of the M1 agonist xanomeline on processing of human beta-amyloid precursor protein (FAD, Swedish mutant) transfected into Chinese hamster ovary-m1 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Muscarinic regulation of Alzheimer's disease amyloid precursor protein secretion and amyloid beta-protein production in human neuronal NT2N cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Convergent cholinergic activities in aging and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

The effect of long-term physostigmine administration in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality, Tacrine Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

Long-term administration of oral physostigmine in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F59.4.308

21 January 2018

Identifiers

DOI

10.1093/JNEN/59.4.308

1 reference

12 May 2018

1 reference

12 May 2018